Migraine in the menopause.

Many women with migraine, especially those with a history of menstrual migraine, experience an exacerbation as they approach menopause. During this time, the orderly pattern of estrogen and progesterone secretion is lost. The fluctuating and falling levels of estrogen during the perimenopausal years may increase the frequency and severity of migraine.

Menstrual migraine. Methods of prevention and control.

In many women, migraine headaches are clearly linked to estrogen levels: the incidence rises at the menarche; attacks may be precipitated by falling estrogen levels before menses; and symptoms usually improve during pregnancy when there are noncyclic high levels of estrogen. Decreased estrogen production in the perimenopausal phase may trigger an exacerbation of migraine. However, after menopause when estrogen levels are noncyclic and low, there may be an improvement in migraine.

The effects of naltrexone, an oral beta-endorphin antagonist, in children with the Prader-Willi syndrome.

Children with the Prader-Willi syndrome have severe and often intractable hyperphagia unresponsive to medical or surgical treatment. Although the effect of opioid antagonists on suppressing appetite in humans has been inconsistent, we evaluated the effectiveness of a new opioid antagonist, naltrexone, in suppressing appetite in four obese adolescents with the Prader-Willi syndrome. Data were collected during the double blind oral administration of the drug and placebo for two 7-day periods.